DNLI Stock — Denali Therapeutics Inc.

Denali Therapeutics Inc. (DNLI)

Updated October 16, 2026.

DNLI is a Stock. Total return is -17.9% over the past 8.9 years, 247.8 points behind SPY at 229.9%.

Denali Therapeutics is a biopharmaceutical company discovering and developing therapeutics for neurodegenerative and lysosomal storage diseases, with pipeline programs targeting conditions including Parkinson's disease, Alzheimer's disease, frontotemporal dementia, and various rare genetic disorders through multiple therapeutic modalities. The company does not currently distribute dividends to shareholders. This security appeals to investors seeking exposure to early-stage biotech development with no income component, where returns depend on clinical trial success and eventual commercialization of its pipeline candidates.

DNLI performance versus SPY

Price and return data through 2026-10-16.

Total return is -17.9% over the past 8.9 years, 247.8 points behind SPY at 229.9%. Over the past year its total return — price change plus distributions reinvested — is 5.3%. Its deepest 1-year drawdown was 35.3%.

DNLI key facts

Asset type

Stock

Asset class

Equity

Inception date

12/08/2017

Distribution frequency

None

Last close

$17.61 (as of 2026-10-16)

Market cap

$2,814,912,767

Average volume

2304258.0

Beta

1.024

Payout ratio

0.0%

EPS

$-2.76

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

DNLI risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 35.3%.

Who may consider DNLI — and who may not

It is a weaker fit for investors who need monthly cash flow (DNLI does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on DNLI

• All tickers starting with D

Tagged: Healthcare.

Frequently asked questions